Market research
ONVO Organovo Holdings Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 64.8
- Dividend yield
- Not available
- Beta
- 1.13
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68620A2033
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 64.8
- Dividend yield
- Not available
- Beta
- 1.13
About
About Organovo Holdings Inc
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONVO discussion.
5 years, 4 months ago
Organovo Holdings, Inc is currently in a long term downtrend where the price is trading 20.1% below its 200 day moving average.
From a valuation standpoint, the stock is 79.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 280.5.
Organovo Holdings, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 25.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 1873.1% to $-12M since the same quarter in the previous year.
Based on the above factors, Organovo Holdings, Inc gets an overall score of 2/5.